TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19827910

Group type: EXPERIMENTAL
Intervention: Pioglitazone/metformin fixed-dose combination (FDC) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone/metformin FDC therapy
Number of subjects: 0
Study: 16913318

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (thermodilution via pulmonary artery catheter)
Number of subjects: 0
Study: 14742288

Group type: EXPERIMENTAL
Intervention: Use of cellular telephones for 10 years or more
Number of subjects: 318

Group type: COMPARATOR
Intervention: Short-term cellular telephone users
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Typical side of head used for cell phone
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Size of tumor
Number of subjects: 318
Study: 12076550

Group type: EXPERIMENTAL
Intervention: Virtual outreach
Number of subjects: 2094

Group type: COMPARATOR
Intervention: Standard outpatient appointments
Number of subjects: 2094
Study: 9861140

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg‐1
Number of subjects: 27

Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 27

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 27
Study: 7495240

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Locally applied beta‐trans retinoic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 30
Study: 2253571

Group type: EXPERIMENTAL
Intervention: Diprivan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 40
Study: 388395

Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tienilic acid (24 months)
Number of subjects: 30
Study: 6313376

Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg daily for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg daily
Number of subjects: 50
Study: 29352654

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard Treatment Control (CON)
Number of subjects: 11
Study: 29628560

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 120
Study: 27955689

Group type: EXPERIMENTAL
Intervention: MAT + A-CHESS
Number of subjects: 440

Group type: COMPARATOR
Intervention: MAT
Number of subjects: 440
Study: 25385729

Group type: EXPERIMENTAL
Intervention: R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)
Number of subjects: 379

Group type: COMPARATOR
Intervention: R-CHOP (rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone)
Number of subjects: 379
Study: 22577905

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in obese group (BMI ≥ 27.5 kg/m(2))
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in non-obese group (BMI <27.5 kg/m(2))
Number of subjects: 108
Study: 20795382

Group type: EXPERIMENTAL
Intervention: Bubo-M vaccine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bubo-M vaccine and hepatitis B vaccine
Number of subjects: 63
Study: 17510847

Group type: EXPERIMENTAL
Intervention: Home safety kit plus home visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home safety kit only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 16238909

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 290

Group type: COMPARATOR
Intervention: Lopinavir 400 mg boosted with ritonavir 100 mg twice daily
Number of subjects: 290
Study: 12056230

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10072409

Group type: EXPERIMENTAL
Intervention: Endoscopic retreatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study: 8771126

Group type: EXPERIMENTAL
Intervention: Standard Laserdish lead (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platinum-iridium coated modified Laserdish electrode (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platinum-iridium coated dish electrode without laser pores (Group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrode with pores and platinum-iridium coating (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electrode with pores (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Platinum-iridium alone (Group C)
Number of subjects: 30
Study: 2205598

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium Carbonate
Number of subjects: 0
Study: 7017103

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by periodontal surgery (modified Widman flap)
Number of subjects: 17
Study: 31556454

Group type: EXPERIMENTAL
Intervention: iNIBP™
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional non-invasive blood pressure monitor
Number of subjects: 66
Study: 29792081

Group type: EXPERIMENTAL
Intervention: Researcher-developed treatment (small-group tutoring for 30 to 45 minutes for an average of 68 lessons, mean hours of instruction = 44.4, SD = 11.2)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Business-as-usual (BAU) comparison condition
Number of subjects: 280
Study: 28838679

Group type: EXPERIMENTAL
Intervention: Artificial saliva (AS) with xylitol, sorbitol, maltitol, mannitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial saliva (AS) with CPP-ACP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial saliva (AS) without polyols
Number of subjects: 0
Study: 25983187

Group type: EXPERIMENTAL
Intervention: Teachable moment brief intervention plus usual care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 50
Study: 25746781

Group type: EXPERIMENTAL
Intervention: Understanding of randomization
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Understanding of placebo use
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Understanding of double-blinding
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Understanding of personal implications of study procedures
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Combined understanding of randomization, double-blinding, and placebo use
Number of subjects: 203
Study: 22878802

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents
Number of subjects: 171
Study: 19506270

Group type: EXPERIMENTAL
Intervention: Prenatal multimicronutrient supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron-folic acid supplementation
Number of subjects: 0
Study: 17532398

Group type: EXPERIMENTAL
Intervention: Adenosine (1.5 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (as control)
Number of subjects: 60
Study: 15466673

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg intramuscular) every 2 weeks for 1 month
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lupron plus placebo (sesame oil as color-matched vehicle)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lupron (7.5 mg intramuscularly) every 4 weeks for 3 months
Number of subjects: 31
Study: 11552002

Group type: EXPERIMENTAL
Intervention: CSF filtration (CSFF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 37
Study: 9630124

Group type: EXPERIMENTAL
Intervention: Cadaveric donor renal transplant pathway
Number of subjects: 348

Group type: COMPARATOR
Intervention: Living donor renal transplant pathway
Number of subjects: 348
Study: 7910724

Group type: EXPERIMENTAL
Intervention: Ketoconazole + Sucralfate (1.0 g) administered simultaneously with 240 ml of water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoconazole administered 2 hours after Sucralfate (1.0 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketoconazole administered with 240 ml of water
Number of subjects: 12
Study: 3582724

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone/10% urea cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 0
Study: 30156354

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR) program
Number of subjects: 59

Group type: COMPARATOR
Intervention: Resource and referral control condition
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Parental sensitive and responsive behavior
Number of subjects: 59
Study: 29903303

Group type: EXPERIMENTAL
Intervention: Intervention group (86 participants)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Intervention group (non-intenders)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Intervention group (intenders)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Intervention group (actors)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (98 participants)
Number of subjects: 184
Study: 25816046

Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional cognitive behavioral therapy (CCBT)
Number of subjects: 132
Study: 23078631

Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux (3.0 mg)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg)
Number of subjects: 276
Study: 21453509

Group type: EXPERIMENTAL
Intervention: Minimal intervention (pedometer based walking programme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximal intervention (pedometer based walking programme)
Number of subjects: 0
Study: 19422337

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 192
Study: 16934051

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily for 4 days
Number of subjects: 9
Study: 15055018

Group type: EXPERIMENTAL
Intervention: Phyto-oestrogens (soya isoflavones: genistein and daidzein) for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phyto-oestrogens after placebo for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo after phyto-oestrogens for 3 months
Number of subjects: 50
Study: 10776362

Group type: EXPERIMENTAL
Intervention: Step Test Exercise Prescription (STEP)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Counseling using the American College of Sports Medicine guidelines (control)
Number of subjects: 400
Study: 9176463

Group type: EXPERIMENTAL
Intervention: Discontinuous-long protocol (n = 68) with GnRH agonist administered from luteal phase until cycle day 7, followed by pure FSH administration.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Long protocol (n = 69) with GnRH agonist administered until the day before hCG administration.
Number of subjects: 92
Study: 1363221

Group type: EXPERIMENTAL
Intervention: F2/E2 group (fentanyl 2 micrograms.kg‐1 and esmolol 2 mg.kg‐1)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: F5 group (fentanyl 5 micrograms.kg‐1)
Number of subjects: 99

Group type: COMPARATOR
Intervention: E2 group (esmolol 2 mg.kg‐1)
Number of subjects: 99

Group type: COMPARATOR
Intervention: F2 group (fentanyl 2 micrograms.kg‐1)
Number of subjects: 99
Study: 3899964

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no relaxation training)
Number of subjects: 72
Study: 30804464

Group type: EXPERIMENTAL
Intervention: Chlorthalidone-based stepped care therapy
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 30003628

Group type: EXPERIMENTAL
Intervention: Norwegian psychomotor physiotherapy (NPMP) once weekly for 6 months
Number of subjects: 105

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 105
Study: 25935830

Group type: EXPERIMENTAL
Intervention: Healthy Recovery intervention (8-session group-based intervention delivered over 5 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (treatment as usual)
Number of subjects: 0
Study: 23357150

Group type: EXPERIMENTAL
Intervention: Weekly lipid apheresis by cascade plasma filtration (CPF) plus atorvastatin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Atorvastatin alone (control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Weekly lipid apheresis by cascade plasma filtration (CPF)
Number of subjects: 34
Study: 21407127

Group type: EXPERIMENTAL
Intervention: β-alanine plus sodium bicarbonate (BASB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: β-alanine alone (BAMD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus sodium bicarbonate (PSB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PMD)
Number of subjects: 20
Study: 19874992

Group type: EXPERIMENTAL
Intervention: High-dose modified-release nicotinic acid (2 g daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 18210887

Group type: EXPERIMENTAL
Intervention: Combined treatment group (hepatectomy plus radiofrequency ablation and 125I implantation)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (hepatectomy alone)
Number of subjects: 78
Study: 14648180

Group type: EXPERIMENTAL
Intervention: Bromocriptin (7.5 mg) combined with clomiphene citrate (150 mg on days 5-9)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo combined with clomiphene citrate (150 mg on days 5-9)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bromocriptin (7.5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11528493

Group type: EXPERIMENTAL
Intervention: Calcium carbonate‐fortified Horlicks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Calcium naturally present in milk
Number of subjects: 16
Study: 8165811

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. orally for 3 months in addition to oral litholysis (OLL) with ursodeoxycholic acid 500 mg/day and chenodeoxycholic acid 500 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral litholysis (OLL) only
Number of subjects: 48
Study: 3077322

Group type: EXPERIMENTAL
Intervention: 2 ppm nitrogen dioxide (Year 1)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 3 ppm nitrogen dioxide (Year 2)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 2 ppm nitrogen dioxide (Year 3)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 1 ppm nitrogen dioxide (Year 3)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Clean air (Year 1)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Clean air (Year 2)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Clean air (Year 3)
Number of subjects: 152
Study: 31658460

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 27
Study: 29651862

Group type: EXPERIMENTAL
Intervention: β-alanine
Number of subjects: 11
Study: 28177671

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg daily for 7 days
Number of subjects: 30
Study: 26494972

Group type: EXPERIMENTAL
Intervention: TRE (telephone-based re-education)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (no TRE)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: TRE
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study: 23286756

Group type: EXPERIMENTAL
Intervention: α‐tocopherol supplementation (50 mg/day)
Number of subjects: 29127

Group type: COMPARATOR
Intervention: β‐carotene supplementation (20 mg/day)
Number of subjects: 29127
Study: 21663925

Group type: EXPERIMENTAL
Intervention: 402 IU/d of vitamin D for 1 year
Number of subjects: 88

Group type: COMPARATOR
Intervention: No vitamin D prophylaxis
Number of subjects: 88
Study: 18421801

Group type: EXPERIMENTAL
Intervention: 0.2 mg s.c. scopolamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4 mg s.c. scopolamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.6 mg s.c. scopolamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16585866

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen 7.5/750 mg
Number of subjects: 40
Study: 12679702

Group type: EXPERIMENTAL
Intervention: Universal nevirapine (NVP) therapy
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Targeted nevirapine (NVP) therapy
Number of subjects: 1524
Study: 10857891

Group type: EXPERIMENTAL
Intervention: Standard antiemetic prophylaxis during cisplatin chemotherapy
Number of subjects: 509
Study: 9296889

Group type: EXPERIMENTAL
Intervention: i.v. injection of heparin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no diabetes)
Number of subjects: 12
Study: 8273601

Group type: EXPERIMENTAL
Intervention: Directed biopsy
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Random biopsy
Number of subjects: 570
Study: 3304386

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Felodipine (in a separate open study)
Number of subjects: 12
Study: 31566845

Group type: EXPERIMENTAL
Intervention: Decipher score
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: RALP GGG
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: MRI‐lesion‐percentage
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Decipher+Surgery variables
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: MRI + Surgery variables
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Relative lesion volume measured on mpMRI
Number of subjects: 91
Study: 28753078

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 15

Group type: COMPARATOR
Intervention: FCAA
Number of subjects: 15
Study: 27383814

Group type: EXPERIMENTAL
Intervention: Antibiotic Prophylaxis (AP+)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Triclosan-Coated Sutures (TCS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional Sutures (CS)
Number of subjects: 74
Study: 26048976

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 24158898

Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen (40 mg of pantoprazole, 1 g of amoxicillin for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Standard 14-day therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen
Number of subjects: 231

Group type: COMPARATOR
Intervention: Standard 14-day therapy
Number of subjects: 231
Study: 21424566

Group type: COMPARATOR
Intervention: Conventional bowel preparation (full cathartic dose and oral contrast medium for 3 days prior to study)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reduced bowel preparation (oral contrast medium administered only on the day of investigation)
Number of subjects: 80
Study: 18376691

Group type: EXPERIMENTAL
Intervention: BCAA-enriched TPN (30% BCAA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard TPN (24% BCAA)
Number of subjects: 64
Study: 16637077

Group type: EXPERIMENTAL
Intervention: Screening arm (n=21,210 men)
Number of subjects: 21210
Study: 14644714

Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogels
Number of subjects: 281

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 281
Study: 11004031

Group type: EXPERIMENTAL
Intervention: Perflubron emulsion IV (1.2 g PFC/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Perflubron emulsion IV (1.8 g PFC/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (3 mL/kg) control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Perflubron emulsion (both dosages)
Number of subjects: 48
Study: 8400072

Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted dosing (Group 2)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Pharmacist-directed dosing (Group 3)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Usual physician‐directed dosing (Group 1)
Number of subjects: 243
Study: 3536490

Group type: EXPERIMENTAL
Intervention: Labetalol at a dose of 0.8 mg kg‐1 (Group II)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard anaesthesia (thiopentone, pancuronium, fentanyl and nitrous oxide) (Group I)
Number of subjects: 24
Study: 29537453

Group type: EXPERIMENTAL
Intervention: Topical Tavaborole
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 102
Study: 27177493

Group type: EXPERIMENTAL
Intervention: Mepolizumab (75 mg, 250 mg, or 750 mg intravenously; 75 mg intravenously or 100 mg subcutaneously)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Mepolizumab (≥150 cells per μL)
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Mepolizumab (≥500 cells per μL)
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Mepolizumab (<150 cells per μL)
Number of subjects: 1192
Study: 24382064

Group type: COMPARATOR
Intervention: Continuing co-trimoxazole prophylaxis
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Stopping co-trimoxazole prophylaxis
Number of subjects: 758
Study: 22305462

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Aspirin (81‐324 mg per day)
Number of subjects: 5599

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 5599